| Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics |
22 |
| Emerging drugs for treating the acute respiratory distress syndrome |
11 |
| Emerging drugs for migraine treatment: an update |
10 |
| An update on emerging drugs in osteosarcoma: towards tailored therapies? |
10 |
| Emerging drugs for the treatment of Dravet syndrome |
9 |
| PARP inhibitors for homologous recombination-deficient prostate cancer |
8 |
| Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma |
7 |
| An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis |
7 |
| Emerging PEGylated non-biologic drugs |
7 |
| Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors |
6 |
| Emerging drugs for the treatment of hypercholesterolemia |
6 |
| Emerging protein kinase inhibitors for the treatment of multiple myeloma |
5 |
| Emerging drugs for primary Sjogren's syndrome |
5 |
| An update: emerging drugs for tinnitus |
5 |
| Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer |
5 |
| Novel therapeutic approaches in primary hyperoxaluria |
5 |
| An update on emerging drugs for the treatment of erectile dysfunction |
4 |
| An update: emerging drugs to treat squamous cell carcinomas of the head and neck |
4 |
| Emerging drugs for primary progressive multiple sclerosis |
4 |
| Emerging reverse transcriptase inhibitors for HIV-1 infection |
4 |
| Expert opinion on emerging urate-lowering therapies |
4 |
| Expert opinion on existing and developing drugs to treat female sexual dysfunction |
4 |
| Emerging drugs for EGFR-mutated non-small cell lung cancer |
3 |
| Emerging molecular target antagonists for the treatment of biliary tract cancer |
3 |
| Emerging drugs for focal epilepsy |
3 |
| Emerging angiogenesis inhibitors for non-small cell lung cancer |
3 |
| New immunotherapy in the treatment of advanced renal cancer |
2 |
| Emerging drugs for eosinophilic esophagitis |
2 |
| Emerging antibiotics for community-acquired pneumonia |
2 |
| Emerging serine-threonine kinase inhibitors for treating ovarian cancer |
2 |
| Emerging drugs for the treatment of onychomycosis |
2 |
| Emerging drugs for the treatment of noninfectious uveitis |
2 |
| Emerging drugs for treating methicillin-resistant Staphylococcus aureus |
2 |
| Emerging drugs for the treatment of axial spondyloarthritis |
2 |
| Emerging drugs for the treatment of Myelofibrosis |
2 |
| Emerging drugs for alopecia areata: JAK inhibitors |
1 |
| Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia |
1 |
| Emerging treatment options for uterine fibroids |
1 |
| Factor XI inhibition fulfilling the optimal expectations for ideal anticoagulation |
1 |
| Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective |
1 |
| Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer |
1 |
| Emerging drugs for progressive supranuclear palsy |
1 |
| Emerging antibacterial and antiviral drugs for treating respiratory tract infections |
1 |
| Emerging PARP inhibitors for treating breast cancer |
1 |
| Emerging drugs for essential thrombocythemia |
0 |
| Emerging pharmacotherapies for the treatment of atrial fibrillation |
0 |
| Emerging growth factor receptor antagonists for ovarian cancer treatment |
0 |
